Tolerability of palbociclib in younger and older patients with advanced breast cancer.
Taylor DennisonHillary HeilingAllison DealKelly BrunkRyan M KemperDaniel J CronaAimee FasoPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Age (<60 vs. ≥60 years) was not associated with the rate of palbociclib dose reductions or discontinuations secondary to neutropenia. Older (≥60 years) patients were more likely to start palbociclib at lower doses which may impact neutropenia and non-neutropenic intolerance.